Abstract:Calcium-activated chloride channels (CaCCs) as a kind of widely expressed ion channels play crucial roles in a variety of physiological regulation. TMEM16A has been identified as the molecular basis of CaCCs in numerous cell types and is considered a new drug target for many diseases. Regulating the function of TMEM16A through small molecule modulators has become a new strategy to improve respiratory and digestive dysfunction and even tumor therapy. Herein, we obtained 5 sesquiterpenoids, named curzerenone, curdione, furanodienone, curcumol and germacrone with TMEM16A inhibition and revealed their mechanism of action by fluorescent and electrophysiological assays. Cell-based YFP fluorescence data demonstrated that 5 compounds inhibited TMEM16A-mediated I− influx in a dose-dependent manner. To explore the mechanism of 5 compounds on CaCCs, FRT cells with high expression of TMEM16A, HBE, HT-29 and T84 cells and mouse colons were used in short-circuit current assay. Our results showed that 5 compounds inhibited the Ca2+-activated Cl− currents generated by the Eact, ATP and UTP stimulation, and this inhibitory effect was related not only to the direct inhibition of channel opening, but also the inhibition of intracellular Ca2+ concentration and K+ channel activity. In addition to CaCCs, these 5 compounds also had definite inhibitory activities against cystic fibrosis transmembrane regulator (CFTR) at the cellular level. In summary, these compounds have the potential to regulate the activites of TMEM16A/CaCCs and CFTR channels in vitro, providing a new class of lead compounds for the development of drugs for diseases related to chloride channel dysfunction.

Synthesis of AC1903 analogs as potent transient receptor potential canonical channel 4/5 inhibitors and biological evaluation

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Discovery of novel modulators targeting human TRPC5: Docking-based virtual screening, molecular dynamics simulation and binding affinity predication

Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay

Cell Active and Functionally-Relevant Small-Molecule Agonists of Calcitonin Receptor.

Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.

Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐chloroquinazoline As Potential EGFR‐TK Inhibitors

Structural Basis for Human TRPC5 Channel Inhibition by Two Distinct Inhibitors.

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

Pharmacological and genetic inhibition of TRPC6-induced gene transcription

TRPC4/5 inhibitors: Phase I results and proof of concept studies

A Precise Microfluidic Assay in Single‐Cell Profile for Screening of Transient Receptor Potential Channel Modulators

Inhibitory activities of curzerenone, curdione, furanodienone, curcumol and germacrone on Ca2+-activated chloride channels

Re-evaluation of some popular CRAC channel inhibitors structurally similar but mechanistically different?

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.